Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 16/20 | 0.50 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.43 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.43 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.43 |
| ▸ | PRKCG | P05129 | 1/20 | 0.43 |
| ▸ | PIM1 | P11309 | 1/20 | 0.43 |
| ▸ | GSK3A | P49840 | 1/20 | 0.43 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.43 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.43 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.43 |
| ▸ | BRSK1 | Q8TDC3 | 1/20 | 0.43 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.43 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6836856 | 0.87 | PARP1 (0.51) | PARP1AURKBPARP2AURKA | |
| SCHEMBL6843638 | 0.80 | PARP1 (0.49) | PARP1RIPK1AURKBPARP2PRKD3 | |
| SCHEMBL461964 | 0.77 | PARP1 (0.58) | PARP1PARP2 | |
| SCHEMBL12385320 | 0.76 | PARP1 (0.62) | PARP1AURKBPARP2PRKD3PIM1 | |
| SCHEMBL23581692 | 0.75 | PARP1 (0.66) | PARP1AURKBPRKD3PIM1GSK3A | |
| SCHEMBL29180021 | 0.73 | PARP1 (0.73) | PARP1AURKBPARP2AURKA | |
| SCHEMBL6841121 | 0.72 | PARP1 (0.56) | PARP1AURKBPARP2PIM1PIM3 | |
| SCHEMBL3088639 | 0.72 | PARP1 (0.87) | PARP1RIPK1 | |
| SCHEMBL3091018 | 0.72 | PARP1 (0.87) | PARP1RIPK1 | |
| SCHEMBL25022851 | 0.71 | PARP1 (0.63) | PARP1AURKBPARP2PRKD3PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040034078-A1 | Benzimidazole inhibitors of poly(ADP-ribosyl) polymerase | AGOURON PHARMACEUTICALS, INC. | 2004-02-19 | — | — | US | disclosed |
| WO-2003106430-A1 | BENZIMIDAZOLE INHIBITORS OF POLY(ADP-RIBOSYL) POLYMERASE | PFIZER INC. (US) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034078-A1 | Benzimidazole inhibitors of poly(ADP-ribosyl) polymerase | PARP1, PARP11, PARP2 | PARP1 1/4885RIPK1 1119/4885AURKB 549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.